A Markov model of fibrosis development in nonalcoholic fatty liver disease predicts fibrosis progression in clinical cohorts

• Egile Nagusiak: Jane Knöchel (Egilea), Linnéa Bergenholm (Egilea), Eman Ibrahim (Egilea), Stergios Kechagias (Egilea), Sara Hansson (Egilea), Mathias Liljeblad (Egilea), Patrik Nasr (Egilea), Björn Carlsson (Egilea), Mattias Ekstedt (Egilea), Sebastian Ueckert (Egilea)
• Formatua: Liburua
• Argitaratua: Wiley, 2023-12-01T00:00:00Z.
• Gaiak: article
• Sarrera elektronikoa: Connect to this object online.

Abstract Disease progression in nonalcoholic steatohepatitis (NASH) is highly heterogenous and remains poorly understood. Fibrosis stage is currently the best predictor for development of end‐stage liver disease and mortality. Better understanding and quantifying the impact of factors affecting NASH...